News

Syngenta Seeds and BioTrove Establish Genomics Technology Relationship To Accelerate Seed Breeding for Agriculture

Syngenta Seeds and BioTrove Establish Genomics Technology Relationship To Accelerate Seed Breeding for Agriculture
 

New Agreement for OpenArrayTM Technology Enables Rapid, Accurate Data Analysis Across Syngenta Seeds Businesses

Golden Valley, MN and Woburn, MA, May 8, 2007 – Syngenta Seeds, Inc. and BioTrove, Inc. today announced a new agreement for BioTrove to supply Syngenta with advanced genomics technology to accelerate Syngenta’s R&D and breeding programs across all of its seeds businesses.

Under the agreement, BioTrove will supply Syngenta with the OpenArrayTM system, a high density, through-hole, nanotiter plate used for conducting genotyping analyses in a microarray format. The new technology will be used in Syngenta’s two largest seed R&D and breeding labs: Slater, Iowa (corn and soybeans) and Toulouse, France(vegetables, diverse field crops, flowers).  Financial terms of the agreement were not disclosed.

“With this technology, we will be able to analyze millions of genome samples within the same time and space parameters that previously allowed us to analyze only thousands,” said Ray Riley, Global Head of Product Development, Syngenta Seeds.  “By conducting massively parallel analyses across all of our seed breeding programs, gathering more data more rapidly, these  process technologies add power to the Syngenta program to bring more and better seed products to market faster.  Our engagement with BioTrove signals a new level of capability in the research and development programs that underpin our global seeds businesses.”

The two companies have worked together on earlier corn and soybean molecular analysis projects, but this agreement marks BioTrove’s first major venture into agriculture genomics, formalizing and broadening the relationship.  Syngenta is the global leader in flower seeds, second in vegetable seeds, and third in field crop seeds including corn and soybean.  Working from best-in-class germplasm bases across all of its seeds businesses, the company is a leading player in the next wave of opportunity in seed science: harnessing the genetic richness of plants for the benefit of growers and consumers.

“At BioTrove, we dedicate ourselves to enabling accelerated research across multiple life science fields,” said Al Luderer, Ph.D., president and CEO, BioTrove.  “Collaborating with an industry leader like Syngenta marks an important company milestone, not only as evidence of the quality of our OpenArray platform, but as demonstration of the value advanced BioTrove technology brings to the agriscience field.”

About BioTrove, Inc.

BioTrove, Inc. offers two innovative technology platforms: RapidFireTM, which enable the acceleration of drug discovery and pipeline decisions, and OpenArrayTM, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health.  With more than half of the world’s ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove’s products and services ensure that an industry committed to accuracy and speed can meet business goals.

RapidFireTM Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput.  RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.

The OpenArrayTM Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArrayTM system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.

For more information, please visit www.biotrove.com or contact:

Dr. Albert A. Luderer, President and CEO
BioTrove, Inc.
781-721-3600
info@biotrove.com

Arielle Bernstein
Makovsky + Company
212-508-9643
abernstein@makovsky.com

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184